ArticleHemaSphere2024
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.
Article in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Indications for Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: State of the Art.Journal of clinical medicine · 2026Review
- Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP-SMAD Signaling to Therapeutic Modulation.Biomolecules · 2026Review
- End-to-end pipeline for automated heart failure diagnosis with clinical notes using SNOMED-CT.Scientific reports · 2026Article
- Artificial Intelligence in Cardiovascular Medicine: A Giant Step in Personalized Medicine?Journal of personalized medicine · 2026Review
- BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.Biomolecules · 2026Review
- Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.Hematology reports · 2025Article
- Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk.Annals of hematology · 2025Review
- QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.Leukemia · 2025Article
- Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Exploring perceptions in the management and treatment of polycythaemia vera in the UK.Annals of hematology · 2025Article
- Acute heart failure in patients with hematologic malignancies: A nationwide analysis 2016-2021.SAGE open medicine · 2025Article
- Emergencies in Hematology: Why, When and How I Treat?Journal of clinical medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.